. Data Demonstrate Potential of GKT831 to Efficiently Target Cancer Associated Fibroblasts
. Interim results of the Phase 2 Trial with GKT831 in Primary Biliary Cholangitis expected in early November 2018
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today the presentation of preclinical data showing that GKT831, the Company’s clinical stage NOX1 and NOX4 inhibitor, efficiently targeted cancer associated fibroblasts (CAFs) in prostate cancer and abrogated the pro-tumorigenic influence of the tumor micro-environment.
More information on : https://www.newcontact.eu/secure/media/com_newcap/files/files/PR_Genkyotex_ESUR18_EN.pdf